PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-62.27%
R&D reduction while CRVO shows 5.59% growth. Joel Greenblatt would examine competitive risk.
43.14%
G&A growth 1.1-1.25x CRVO's 37.03%. Bill Ackman would demand evidence of necessary spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.75%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-7.75%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
-100.00%
Interest expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
975.86%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
-265.35%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
7.75%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-2437.42%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-313.81%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-313.81%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-286.19%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-286.19%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
6.89%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
6.89%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.